Patents Represented by Attorney, Agent or Law Firm W. Murray Spruill
-
Patent number: 6605450Abstract: Methods and compositions for the expression of nucleotide sequences are provided. Compositions comprise the nucleic acid sequences of the transcriptional regulatory region of the PpSEC10 gene of Pichia pastoris. Methods are provided to chemically regulate the PpSEC10 transcriptional control region by modulating the iron concentration in the culturing medium. The methods find use in regulating expression of nucleotide sequences. Furthermore, the methods of the invention can be used to regulate polypeptide expression, more particularly in regulating heterologous polypeptide expression, particularly using a yeast host cell as the expression system.Type: GrantFiled: May 24, 2001Date of Patent: August 12, 2003Assignee: Chiron CorporationInventors: Robert J. Bishop, Kenneth A. Crawford, Margaret M. Worden
-
Patent number: 6579521Abstract: Methods for promoting immunologic control of human immunodeficiency virus (HIV) in an HIV-infected subject are provided. The methods comprise administering to the subject highly active antiretroviral therapy (HAART) for at least one cycle of an intermittent dosing regimen in combination with administration of a pharmaceutical composition comprising a therapeutically effective amount of interleukin-2 (IL-2) or variant thereof. The combination of daily or intermittent administration of IL-2 (or variant thereof) and intermittent HAART promotes immunologic control of viral replication in the absence of HAART, thereby prolonging the length of time a patient may discontinue HAART before viral rebound necessitates further administration of HAART. Administration of IL-2 therapy in combination with an intermittent HAART dosing regimen provides an effective method for treating a subject infected with HIV.Type: GrantFiled: October 9, 2001Date of Patent: June 17, 2003Assignee: Chiron CorporationInventor: David Sahner
-
Patent number: 6512102Abstract: The invention is generally directed to compositions and methods for affecting signal transduction using the casein kinase I (CKI) gene or gene product. The invention is more specifically directed to affecting the Wnt signal pathway using the CKI gene or gene product. The invention is particularly directed to using the CKI gene or gene product to treat and diagnose cancer, particularly breast and colon cancer. CKI&egr; is the preferred species. The field of the invention is compositions and methods for modulating signal transduction using the (CKI) gene or gene products and variants thereof. The invention is more specifically directed to modulating the Wnt signal pathway using the CKI gene or gene product. The invention is particularly directed to using the CKI gene or gene product to treat and diagnose disorders mediated by the Wnt signal pathway, especially hyperproliferative disorders, particularly breast and colon cancer.Type: GrantFiled: December 23, 1999Date of Patent: January 28, 2003Assignee: Chiron CorporationInventors: Licen Xu, Stephen D. Harrison, Lewis T. Williams
-
Patent number: 6410264Abstract: Regulatory nucleotide sequences for a novel Pichia pastoris gene, designated PpSEC10 gene, and the nucleotide sequences and respective amino acid sequences for the secretion leader and the mature Sec10p protein components of the precursor polypeptide encoded by this novel gene are provided. These compositions are useful in methods for expression and secretion of proteins when assembled in proper reading frame, individually or in combination, within a DNA construct that further comprises a nucleotide sequence encoding a protein of interest. Vectors comprising the DNA constructs of the invention can be used to transform a yeast host cell, which can then be cultured to obtain the secreted protein of interest. Kits useful in this method and in methods of detection of the Sec10p protein using antibodies are also disclosed.Type: GrantFiled: July 31, 1998Date of Patent: June 25, 2002Assignee: Chiron CorporationInventors: Kenneth A. Crawford, Robert Bishop
-
Patent number: 6407061Abstract: Disclosed is a method for transporting neurologic therapeutic agents to the brain by means of the olfactory neural pathway and a pharmaceutical composition useful in the treatment of brain disorders.Type: GrantFiled: August 16, 1999Date of Patent: June 18, 2002Assignee: Chiron CorporationInventor: William H. Frey, II
-
Patent number: 6342478Abstract: Disclosed is a method for transporting neurologic therapeutic agents to the brain by means of the olfactory neural pathway and a pharmaceutical composition useful in the treatment of brain disorders.Type: GrantFiled: August 16, 1999Date of Patent: January 29, 2002Assignee: Chiron CorporationInventor: William H. Frey, II
-
Patent number: 6313093Abstract: Disclosed is a method for transporting neurologic therapeutic agents to the brain by means of the olfactory neural pathway and a pharmaceutical composition useful in the treatment of brain disorders.Type: GrantFiled: August 16, 1999Date of Patent: November 6, 2001Assignee: Chiron CorporationInventor: William H. Frey, II
-
Patent number: 6180603Abstract: Disclosed is a method for transporting neurologic therapeutic agents to the brain by means of the olfactory neural pathway and a pharmaceutical composition useful in the treatment of brain disorders.Type: GrantFiled: January 8, 1997Date of Patent: January 30, 2001Assignee: Chiron CorporationInventor: William H. Frey, II
-
Patent number: 6107057Abstract: Polynucleotides, vectors, and host cells comprising a polynucleotide having a fragment of a leader sequence and a second nucleotide sequence that encodes a polypeptide heterologous to the leader sequence, wherein the leader sequence fragment is sufficient for secretion and comprises an amino acid sequence that comprises at least about 70% sequence identity to the leader sequence of Pichia acaciae killer toxin, wherein the heterologous polypeptide is not naturally contiguous to the leader sequence, and wherein upon expression of the polynucleotide molecule in a host cell suitable for expression thereof, the heterologous polypeptide is produced that is free of additional N-terminal amino acids.Type: GrantFiled: February 24, 1998Date of Patent: August 22, 2000Assignee: Chiron CorporationInventors: Kenneth Crawford, Isabel Zaror, Robert J. Bishop, Michael A. Innis
-
Patent number: 6083723Abstract: Compositions and methods for expression of heterologous mammalian proteins and their secretion in the biologically active mature form using a yeast host cell as the expression system are provided. Compositions of the invention are nucleotide sequences encoding a signal peptide sequence for a yeast secreted protein, an optional leader peptide sequence for a yeast secreted protein, a native propeptide leader sequence for a mature protein of interest, and a sequence for the mature protein of interest, all operably linked to a yeast promoter. Each of these elements is associated with a processing site recognized in vivo by a yeast proteolytic enzyme. Any or all of these processing sites may be a preferred processing site that has been modified or synthetically derived for more efficient cleavage in vivo. The compositions are useful in methods for expression of heterologous mammalian proteins and their secretion in the biologically active mature form.Type: GrantFiled: July 1, 1999Date of Patent: July 4, 2000Assignee: Chiron CorporationInventor: Patricia Tekamp-Olson
-
Patent number: 6034059Abstract: IGF-1 and a hypocaloric amount of nutrient are used to treat a catabolic state in a patient. The IGF-1 and nutrient can be administered simultaneously, separately or sequentially. The amounts of IGF-1 and hypocaloric amount of nutrient are effective for the treatment of the catabolic state.Type: GrantFiled: March 17, 1993Date of Patent: March 7, 2000Assignee: Chiron CorporationInventors: Linda Fryklund, Peter Gluckman, Anna Skottner
-
Patent number: 5994303Abstract: A combination of insulin and an insulin-like growth factor I (IGF-I) as used in the manufacture of a medicament for counteracting a decrease in nitrogen balance and for counteracting a decrease in protein synthesis. The medicament can be used for the treatment of catabolism which is a protein catabolism due to glucocorticoid excess.Type: GrantFiled: January 5, 1998Date of Patent: November 30, 1999Assignee: Chiron CorporationInventors: Vibeke Arrhenius-Nyberg, Kjell Malmlof, Anna Skottner
-
Patent number: 5922569Abstract: The invention concerns a method for the production of a polypeptide with the aid of genetically engineered yeast cells which contain not more than one functional CUP1 gene in the genome and carry a plasmid comprising a gene coding for said polypeptide and a functional CUP1 gene; and said yeast cells and said plasmids.Type: GrantFiled: May 26, 1995Date of Patent: July 13, 1999Assignee: Ciba-Geigy CorporationInventors: Jutta Heim, Thomas Hottiger, Gabriele Pohlig, Peter Furst
-
Patent number: 5842573Abstract: A method of transporting cells in culture commences with the provisions of a multiwell plastic plate, wherein at least one well contains a sample of cells. A sheet of sterile adhesive film is applied to the top of the plate with sufficient pressure to seal the sample of cells into the well. The sterile adhesive film and the multiwell plate are covered with a plate cover, with a flexible plastic pad being optionally inserted between the sheet of sterile adhesive film and the plate cover. This method can be practiced with a kit containing these components in a unitized package.Type: GrantFiled: March 11, 1997Date of Patent: December 1, 1998Inventor: Yuan-Di C. Halvorsen
-
Patent number: 5814484Abstract: Methods for the expression of mammalian MIP-1.alpha. and MIP-1.beta. are disclosed. The methods generally comprise introducing into a yeast cell, a DNA molecule capable of directing the expression and if desired the secretion of either MIP-1.alpha. or MIP-1.beta.. Methods for expression of constructs encoding both MIP-1.alpha. and MIP-1.beta. are also described. The MIP molecules so produced are biologically active.Type: GrantFiled: January 31, 1995Date of Patent: September 29, 1998Inventors: Patricia Tekamp-Olson, Carol Ann Gallegos
-
Patent number: 5708148Abstract: A process for the preparation of a recombinant IGF-II (rIGF-II) without a covalently attached foreign protein moiety and without N-terminal attached methionine or a derivative of methionine or of a salt of said IGF-II, rIGF-II produced by said method, hybrid vectors comprising DNA encoding said rIGF-II, hosts transformed with said vectors, and a process for the isolation of said rIGF-II from the host cell and refolding it into a biologically active form.Type: GrantFiled: November 16, 1994Date of Patent: January 13, 1998Assignee: CIBA GEIGY CorporationInventors: Albert Schmitz, Walter Marki
-
Patent number: 5708140Abstract: The invention lies in the field of genetic engineering and, in particular, is concerned with the use of 7B2 as chaperone in vivo or in vitro. The invention accordingly concerns a method for producing a desired protein in vivo with the aid of recombinant cells capable of expressing 7B2 and of expressing and secreting said desired protein. Another aspect is accordingly an in vitro method for the deaggregation or prevention of aggregation of protein by treating the protein with 7B2.Type: GrantFiled: September 2, 1994Date of Patent: January 13, 1998Assignee: Ciba-Geigy CorporationInventors: Gerardus Julianus Maria Martens, Bhabatosh Chaudhuri, Christine Stephan
-
Patent number: 5646037Abstract: The invention relates to the field of genetic engineering and provides novel hybrid vectors based on the yeast two micron plasmid. The novel hybrid vectors are stably maintained in the cell during proliferation and are useful for the expression of heterologous genes in yeast in large scale batch and particularly in continuous culture.Type: GrantFiled: November 2, 1994Date of Patent: July 8, 1997Assignee: Ciba-Geigy CorporationInventor: Frank Buxton
-
Patent number: 5641668Abstract: The invention concerns proteins having glycosyltransferase activity, recombinant DNA molecules encoding proteins having glycosyltransferase activity, hybrid vectors comprising such recombinant DNA molecules, transformed hosts suitable for the multiplication and/or expression of the recombinant DNA molecules, and processes for the preparation of the proteins, DNA molecules and hosts.Type: GrantFiled: May 26, 1995Date of Patent: June 24, 1997Assignee: CIBA-GEIGY CorporationInventors: Eric G. Berger, Manfred Watzele, Svetoslav X. Iwanow
-
Patent number: 5516938Abstract: The present invention relates to monoclonal antibodies that are distinguished by a high degree of selectivity and affinity towards herbicides from the group of the sulfonylureas, especially towards sulfonylurea herbicides of formula (A) ##STR1## wherein X is a mono- or di-substituted 6-membered heterocycle having from one to three nitrogen atoms and bonded via carbon, but is preferably mono- or di-substituted s-triazine or pyrimidine; andn is an integer from 0 to 4, preferably the number 1, and that are therefore outstandingly suitable for use in an immunoassay for the rapid and effective detection of the said sulfonylurea herbicides in soil, water or air samples or in plant extracts, and to methods for the production of said monoclonal antibodies.The present invention relates also to hybridoma cell lines that produce said monoclonal antibodies and to immunological detection methods using said monoclonal antibodies, and to test kits that may be used in those detection methods.Type: GrantFiled: January 6, 1995Date of Patent: May 14, 1996Assignee: Ciba-Geigy CorporationInventors: Jean-Marc Schlaeppi, Dietmar Huglin